Nearly 20% of young adults in the United States may have high blood pressure, according to an analysis of the NIH-funded National Longitudinal Study of Adolescent Health (Add Health) published online May 23 in Epidemiology.
Nearly 20% of young adults in the United States may have high blood pressure, according to an analysis of the NIH-funded National Longitudinal Study of Adolescent Health (Add Health) published online May 23 in Epidemiology.
Investigators recorded blood pressure readings of more than 15,000 men and women between 24 and 32 years of age who were enrolled in the study. High blood pressure (hypertension) was defined as 140/90 millimeters of mercury or greater. Respondents were asked whether they had been told by a healthcare professional that they had high blood pressure. Following the interview, they remained seated for 5 minutes and study technicians took 3 readings of their blood pressure. Accuracy of each reading was double-checked and the average of the last 2 readings was entered into the study database.
The authors then examined discordances in hypertension findings between Add Health and the National Health and Nutrition Examination Survey (NHANES) in which a rate of 4% was found among participants of the same age. Although, high blood pressure appeared more prevalent among the Add Health respondents than in the NHANES respondents, the authors found that the proportion of respondents who reported they had been told by a healthcare provider that they had high blood pressure was similar: 11% (Add Health) versus 9% (NHANES).
"We explored several possible explanations for the difference between this study and NHANES, including participant characteristics, where they were examined, and the types of devices for measuring their blood pressure," said Kathleen Mullan Harris, PhD, principal investigator of the study in a press release. "None of these factors could account for the differences in estimates between the 2 surveys."
The study concluded that the findings warranted further scrutiny.
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More